Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy - PulmoPrint

NCT07653438 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT07653438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07653438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy - PulmoPrint
Lead sponsor
University Medical Center Groningen
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
March 1, 2031
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

stage iii non-small cell lung cancer, unresectable stage iii nsclc